Comparable dopamine 2 receptor occupancy.
de Haan
Lieuwe
L
van Amelsvoort
Therese
T
D001569:Benzodiazepines; D003072:Cognition Disorders / Q000139:chemically induced; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D000077152:Olanzapine; D010890:Pirenzepine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D001569:Benzodiazepines; D018492:Dopamine Antagonists; D006220:Haloperidol; D000077152:Olanzapine; D010890:Pirenzepine; D018967:Risperidone; D017367:Selective Serotonin Reuptake Inhibitors